GoldenGolden
CymaBay Therapeutics

CymaBay Therapeutics

A company developing treatments for liver and other chronic dieases

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

May 13, 2021
CymaBay Therapeutics Inc. announces that Dennis D. Kim, MD, MBA, is joining the company as Chief Medical Officer.
April 19, 2007
CymaBay Therapeutics raises a $32,000,000 series D round from AllianceBernstein, Alta Partners, KBC, MPM Capital, Novo Ventures, T. Rowe Price, Venrock and Versant Ventures.

Funding rounds

People

Name
Role
LinkedIn

Laura Byerly

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 10, 2021
BioSpace
Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product Launches Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions
Amirah Al Idrus
November 17, 2020
FierceBiotech
CymaBay Therapeutics is getting its liver disease drug back on track. The treatment beat placebo at lowering a liver enzyme in patients with primary biliary cholangitis (PBC), a rare, progressive disease that can lead to inflammation and scarring in the liver.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.